Skip to Content
Merck
CN

Key Documents

View All Documentation

SML1102

Darifenacin hydrobromide

≥98% (HPLC), Muscarinic antagonist, powder

Synonym(s):

(3S)-1-[2-(2,3-Dihydro-5-benzofuranyl)ethyl]-α,α-diphenyl-3-pyrrolidineacetamide hydrobromide, UK 88525-04

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C28H30N2O2 · HBr
CAS Number:
133099-07-7
Molecular Weight:
507.46
UNSPSC Code:
12352200
PubChem Substance ID:
329825477
NACRES:
NA.77
MDL number:
MFCD08141803
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
100
Storage condition:
desiccated
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Darifenacin hydrobromide, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +41 to +49°, c = 1 in methylene chloride

storage condition

desiccated

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

−20°C

SMILES string

O=C(N)C([C@H]1CN(CCC2=CC=C(OCC3)C3=C2)CC1)(C4=CC=CC=C4)C5=CC=CC=C5.Br

InChI

1S/C28H30N2O2.BrH/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26;/h1-12,19,25H,13-18,20H2,(H2,29,31);1H/t25-;/m1./s1

InChI key

UQAVIASOPREUIT-VQIWEWKSSA-N

Gene Information

human ... CHRM2(1129), CHRM3(1131)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Darifenacin is a muscarinic receptor antagonist. It is an extended release tablet that has 7.5 mg or 15 mg darifenacin as its hydrobromide salt.

Application

Darifenacin hydrobromide has been used to inject experimental animals.

Biochem/physiol Actions

Darifenacin hydrobromide is an antispasmodic muscarinic antagonist, selective for blocking the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions. Darifenacin hydrobromide has 9 and 12-fold greater affinity for M3 compared to M1 and M5, respectively, and 59-fold greater affinity for M3 compared to both M2 and M4. Darifenacin is used clinically to treat urinary incontinence and overactive bladder syndrome.
Darifenacin hydrobromide is an antispasmodic muscarinic antagonist, selective for blocking the M3 muscarinic acetylcholine receptor.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000454105
0000454105
0000441490
0000441490
0000376980

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Evaluating the effect of three newly approved overactive bladder syndrome treating agents on parotid and submandibular salivary glands: Modulation of CXCL10 expression
Aboulhoda BE and Ali EN
Acta Histochemica, 120(3), 269-281 (2018)
Principles and Practice of Urology, 2 (2013)
Henry C Liu et al.
The Journal of pharmacology and experimental therapeutics, 359(1), 215-229 (2016-08-05)
Statistical analysis was performed on physicochemical descriptors of ∼250 drugs known to interact with one or more SLC22 "drug" transporters (i.e., SLC22A6 or OAT1, SLC22A8 or OAT3, SLC22A1 or OCT1, and SLC22A2 or OCT2), followed by application of machine-learning methods
Ikunobu Muramatsu et al.
Journal of neurochemistry, 149(5), 605-623 (2019-04-11)
Regulation of neurotransmitter release in the central nervous system is complex. Here, we investigated regulatory mechanisms for acetylcholine (ACh) release from cholinergic neurons by performing superfusion experiments with rat striatal segments after labelling the cellular ACh pool with [3 H]choline.
J Di Salvo et al.
The Journal of pharmacology and experimental therapeutics, 360(2), 346-355 (2016-12-15)
Although the physiologic role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β

Articles

DISCOVER Bioactive Small Molecules for Neuroscience

DISCOVER Bioactive Small Molecules for Neuroscience

Global Trade Item Number

SKUGTIN
SML1102-50MG04061832077024
SML1102-10MG04061837107603

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service